Last reviewed · How we verify
NCT03095482
tDCS-Augmented Exposure Therapy for Pathological Fear
NA trial testing Transcranial Direct Current Stimulation (tDCS) in Specific Phobias in 49 participants. Completed in 6 September 2018.
6 September 2018
Quick facts
| Lead sponsor | University of Texas at Austin |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 49 |
| Start date | 1 January 2017 |
| Primary completion | 6 September 2018 |
| Estimated completion | 6 September 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transcranial Direct Current Stimulation (tDCS)
- In vivo exposure therapy
Conditions studied
- Specific Phobias — all drugs for Specific Phobias →
Sponsor
University of Texas at Austin
Who can join
Adults 18 to 65, any sex, with Specific Phobias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This double-blind randomized controlled clinical trial aims to test whether transcranial direct current stimulation (tDCS) can be used to modulate fear extinction learning during exposure therapy for pathological fear, including fear of spiders, snakes, or germs / contamination. Participation takes place over three laboratory visits, including (1) a pre-treatment visit, (2) a treatment and post-treatment visit, and (3) a 1 month follow-up visit. During treatment, participants will receive either 20 minutes of active or sham tDCS, followed by 30 minutes of in vivo exposure therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03095482
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcranial Direct Current Stimulation (tDCS)
Trials testing the same drug.
- NCT07411833 — tDCS for Stress and Burnout in Higher Education · NA · enrolling by invitation
- NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
- NCT07333404 — Combined tDCS and Pneumatic Compression for Recovery After a 10K Run · NA · not yet recruiting
- NCT07291791 — tDCS for Pain Modulation in Knee Osteoarthritis · NA · active not recruiting
- NCT07116109 — Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Integrated Treatment for Pain and PTS · NA · recruiting
Other University of Texas at Austin trials
Trials by the same sponsor.
- NCT07319234 — Development of MENU Protocol · NA · not yet recruiting
- NCT07480109 — Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity) · NA · not yet recruiting
- NCT07069413 — Sibwatch: Optimizing Intervention Options for Infants and Toddler Siblings of Autistic Children · NA · not yet recruiting
- NCT07370311 — A Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisi · NA · not yet recruiting
- NCT07441122 — Enhancing Attention in Elderly Using a Brain-Computer-Interface · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03095482 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas at Austin
- Last refreshed: 8 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03095482.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing